22 results about "Doxorubicin" patented technology

This application provides a method for preparing pH-responsive polyamino acid drug-loaded nanoparticles based on sarcosine and their application. Sar-NNCA, L-lysine-NCA, and L-phenylalanine-NCA are dissolved in anhydrous DMF and polymerized under argon protection with a hexamethyldisilazine initiator to obtain a polyamino acid block copolymer Sar-NNCA. 80 -Lys(Cbz) n -Phe 10 The crude product was deprotected under HBr / acetic acid and loaded with DOX to obtain Sar. 80 -Lys n -Phe 10 -DOX. This application describes the preparation of a pH-responsive polymer nanoplatform, Sar, by encapsulating doxorubicin in polysarcosine-polylysine-polyphenylalanine nanoparticles via Schiff base bonds. 80 -Lys n -Phe 10 -DOX is used for tumor treatment. These polyamino acid nanoparticles are spherical with an average particle size of approximately 200 nanometers, exhibiting pH-responsive properties, excellent cellular uptake capacity, and anti-tumor effects. In vitro experiments show that Sar... 80 -Lys n -Phe 10 The carrier material exhibits excellent biocompatibility. The newly synthesized Sar... 80 -Lys n -Phe 10 -DOX nanomicelles show promise as a drug delivery system for cancer treatment.

The application discloses a doxorubicin scavenger for protecting ovarian fertility and a preparation method thereof, comprising a DNA complex wrapped by a red blood cell membrane, wherein the red blood cell membrane is surface-modified by an anti-Mullerian duct antibody alphaAMH; the doxorubicin scavenger is specifically combined with AMH which is highly expressed in ovarian tissues through alphaAMH, is enriched in the ovarian part in a targeted manner, adsorbs doxorubicin through a DNA fragment in the DNA complex, reduces toxic damage of doxorubicin to ovarian cells, and further protects ovarian fertility. The doxorubicin scavenger can adsorb injected doxorubicin Dox, reduce side effects of doxorubicin Dox on ovarian granulosa cells, and further protect ovarian function and fertility.

The application discloses a high-safety tumor treatment preparation based on a prodrug-enzyme-neutralizing antibody three-system, and a preparation method and application thereof. The preparation comprises three core components: (a) a prodrug, which is coupled by an anti-tumor drug (such as doxorubicin) and cephalosporin; (b) an activating enzyme, such as beta-lactamase, which is specifically expressed in the tumor by phage, catalyzes the hydrolysis of the prodrug, and releases the active drug; and (c) a neutralizing antibody, such as an anti-doxorubicin monoclonal antibody, which can specifically bind and neutralize the active drug overflowing into the blood circulation. The application first integrates the precise killing strategy of "prodrug-local activation" and the safety strategy of "neutralizing antibody-systematic protection" into a complete treatment closed loop, utilizes the "differential neutralization" characteristics of the anti-doxorubicin antibody, effectively protects normal tissues from toxic damage under the premise of not affecting the local efficacy of the tumor, and significantly improves the therapeutic index of the chemotherapy drug, reduces the side effects such as cardiotoxicity and bone marrow suppression, and provides a new paradigm with high efficiency and safety for tumor treatment.

Described herein are compounds that block the activity of LOX family members having good IC50 values, no cellular toxicity below 10 μM, induce sensitization of the cells to doxorubicin, strong activity in a recombinant LOX / LOXL2 activity, and a chemical structure that is drug-like and does not have a PAINS flag, as well as, methods of treatment using the compounds with respect to cancer, organ fibrosis, neurodegenerative and cardiovascular diseases.

This invention discloses a novel class of peptides for targeted cancer therapy and their corresponding drug or fluorescent dye conjugates, belonging to the field of biomedical technology. These peptides are designed based on the optimized structure of natural LHRH-III, enabling them to specifically bind to and efficiently internalize into tumor cells overexpressing luteinizing hormone-releasing hormone receptor (LHRH-R). After fluorescent conjugation, their targeting ability against 4T1 cells is comparable to that of the classic peptide [D-Lys]. 6 The [-LHRH-I] peptide exhibits comparable to or superior performance and significantly improves cellular internalization efficiency. In vivo distribution studies have shown that its liver accumulation is significantly reduced compared to the control group, effectively lowering the risk of hepatotoxicity. Furthermore, by conjugating the targeting peptide with antitumor drugs (such as camptothecin or doxorubicin) via disulfide linkers, the resulting peptide-drug conjugates (PDCs) demonstrate excellent responsive drug release characteristics and good in vitro and in vivo antitumor activity. The peptides and conjugates provided by this invention have potential application value in cancer targeted therapy and diagnosis with high specificity and low toxicity.

This invention relates to the field of biomedical technology, specifically disclosing a biomimetic exosome derived from tumor cell membranes, its preparation method, and its applications. The preparation method of the biomimetic exosomes derived from tumor cell membranes provided by this invention includes the following steps: mixing LLC-derived cell membranes with doxorubicin and resveratrol solutions, and preparing biomimetic exosomes derived from tumor cell membranes by extrusion. The preparation method provided by this invention has advantages such as wide availability of raw materials, simple and controllable process, low technical threshold, and suitability for industrial-scale production. The biomimetic exosomes provided by this invention can effectively induce a specific immune response against tumor cells, achieving the purpose of inhibiting the progression of primary tumors and prolonging the survival of tumor-bearing mice. It can also promote the polarization of macrophages from a pro-tumor M2 phenotype to an anti-tumor M1 phenotype, laying a favorable foundation for the efficient implementation of subsequent immunotherapy and possessing broad application prospects.

The invention represents new hybrid compounds of two natural products sclareol and doxorubicin in the form of their conjugates. These compounds are in the form of conjugates, where doxorubicin and sclareol are covalently linked by a linker in a 1:1 molar ratio. The hybrids have shown to possess anticancer properties and are effective in treating resistant cancer cells that have P-glycoprotein membrane transporter, responsible for resistance to doxorubicin. The hybrids have been tested on different types of cell lines, including human glioblastoma, non-small cell lung carcinoma, and colorectal carcinoma. Also, a method for their preparation and their use in medical products or pharmaceutical preparations has been determined. The results of the study include the cytotoxic activity of single, combined, and conjugated compounds in pairs of sensitive and resistant cancer cells, with and without P-glycoprotein expression. The selectivity towards cancer cells was determined by comparing with commercially available normal human lung fibroblast cells. The study also investigated the nanoparticle nature of hybrid compounds, their intracellular localization and toxicity in vivo.

The application belongs to the field of new adjuvants and new dosage forms of pharmaceutical preparations, and particularly relates to a type I and type II immunogenic cell death inducer ion pairing engineered nanoassemblies as well as construction and application thereof. The nanoassemblies are composed of type I ICD inducers, type II ICD inducers, hydrophobic auxiliary counterions and amphiphilic lipid ion pairing. The type I ICD inducer is selected from mitoxantrone, doxorubicin, oxaliplatin or cyclophosphamide; the type II ICD inducer is selected from hypericin; and the hydrophobic auxiliary counterion is selected from cholesteryl sodium sulfate, cholic acid, deoxycholic acid, chenodeoxycholic acid, lithocholic acid, glycolcholic acid, taurocholic acid, glycochenodeoxycholic acid, taurochenodeoxycholic acid, deoxycholic acid lysine derivative, oleanolic acid and ursolic acid. The type I and type II ICD inducers are combined in the application, and have a synergistic tumor treatment effect.

The application discloses a preparation method and application of cell membrane-derived nanovesicles with specific targeting tumor and metastasis inhibition. The CD82 overexpression lung epithelial cell HBE cell strain is constructed through gene engineering, cell membranes are extracted in vitro, AS1411 aptamer is modified, and a chemotherapeutic drug, doxorubicin (DOX), is loaded to prepare an engineered nanovesicle drug delivery system. The engineered nanovesicle drug delivery system prepared by the application is proved to have multiple effects such as targeting triple-negative breast cancer, inhibiting metastasis and inducing triple-negative breast cancer cell apoptosis through in-vitro and in-vivo experiments. The application fills the gap of the extracellular vesicles as a drug carrier, and provides a new thought and scientific basis for the clinical treatment of triple-negative breast cancer.

The application provides an antitumor drug, a preparation method and application thereof, and belongs to the technical field of medicines. 4 The Fe3O NPs are deposited with polydopamine on the surface, then a COF layer is formed on the surface through a one-pot method, and an antitumor compound is loaded; further, doxorubicin is loaded on the surface, and then the antitumor drug is prepared by reacting with F127 coupled with folate and oligomeric hyaluronic acid. The antitumor drug prepared by the application has high anticancer activity and drug resistance reversal, high drug loading rate, is not prone to aggregation, has good biocompatibility, good targeting and slow release, and has good application in chemotherapy, photodynamic therapy, photothermal therapy and nuclear magnetic imaging, so that the antitumor drug becomes a new generation of diagnosis and treatment integrated reagent.

This invention discloses a miR-141 / near-infrared light dual-response synergistic drug delivery system, relating to the fields of biomedicine and nanomedicine. The system uses DNA-modified gold nanocages as carriers, loading doxorubicin (a chemotherapy drug) and methylene blue (a photosensitizer). H-type DNA nanolocks formed by thiol-modified A and B chains achieve specific recognition of miR-141 and dual response to near-infrared light. miR-141 binding triggers initial unwinding of the nanolocks, followed by complete unwinding and drug release via 808nm near-infrared light irradiation (photothermal effect). A 650nm laser excites methylene blue to generate reactive oxygen species, simultaneously completing quantitative detection of miR-141 (fluorescence / SERS signal complementarity) and synergistic treatment in three modes: chemotherapy + photothermal + photodynamic therapy. In vitro experiments show a miR-141 detection sensitivity of 5.0 × 10⁻⁶. ‑12 M, with a dual-response drug release rate exceeding 60%; in vivo experiments have demonstrated a tumor inhibition rate exceeding 70% and good biocompatibility. This system solves the problems of single-response and separation of diagnosis and treatment in existing delivery systems, and is suitable for precision treatment of miR-141 positive solid tumors such as MCF-7.

This invention discloses a non-cationic polymer siRNA and chemical drug co-delivery system, comprising a non-cationic polymer and a complex of siRNA and drug loaded on the polymer; the complex is composed of a target siRNA and a corresponding drug; the non-cationic polymer contains several branches with aromatic rings, the aromatic rings being selected from one or more of 5- to 15-membered aromatic rings or 5- to 15-membered heteroaromatic rings; the drug is selected from one or more of gemcitabine, mitoxantrone, topotecan, beloteccan, irinotecan, doxorubicin, camptothecin, and derivatives of any of the above drugs. This invention enables the synergistic delivery of siRNA and chemical drugs, effectively overcoming the cytotoxicity problems caused by cationic delivery systems, and demonstrates promising application prospects in the field of modern drug delivery.

This invention relates to the application of *Hirudo medicinalis* in the preparation of drugs that promote skeletal muscle cell differentiation and / or prevent muscle atrophy, belonging to the field of biomedical technology. The skeletal muscle cells are myoblasts. In vitro, this drug can promote differentiation by upregulating the expression of myosin heavy chain (MyHC), myogenin, and myogenic determinant MyoD, thereby increasing myotube diameter. In vivo, it can improve doxorubicin-induced skeletal muscle atrophy in mice and repair muscle fiber damage caused by natural aging nematodes. The chemotherapeutic drug is doxorubicin, which can exert an anti-atrophy effect by maintaining the expression of myosin heavy chain (MyHC) and improving myotube morphology damage. This invention is the first to discover and experimentally demonstrate that *Hirudo medicinalis* freeze-dried powder has the activity of promoting myoblast differentiation and preventing muscle atrophy, opening up new applications for traditional Chinese medicine leeches in the prevention and treatment of muscle atrophy and expanding the medicinal value of *Hirudo medicinalis*.

The application belongs to the technical field of medicine, and particularly relates to a modularly constructed targeted-tumor-killing polypeptide-drug conjugate as well as a preparation method and application. The conjugate has a dendritic six-branch scaffold structure, and the scaffold can realize replaceable combination of a targeting polypeptide and a chemotherapeutic drug through chemical modification, so that precise drug delivery can be realized for different tumor types. Among them, a blood vessel binding peptide and an albumin binding peptide are selected as model polypeptides, and a common clinical drug doxorubicin is selected as a model drug. The polypeptide-drug conjugate has high drug loading and stability, can improve the pharmacokinetic characteristics of poorly soluble drugs, prolong in-vivo circulation, has small molecular weight and strong tissue permeability, can be precisely enriched in tumors, has good structural adjustability and functional expansion potential, and exhibits significant anti-tumor effect and safety.

This invention discloses a copper nanoparticle-based SERS sensor, its preparation method, and its application in trace detection of doxorubicin. The sensor comprises a porous anodic alumina substrate, metal halide-oxide nanosheets vertically grown on its surface, and copper nanoparticles uniformly deposited on the surface and sidewalls of the nanosheets via atomic layer deposition (ALD). The preparation method involves first preparing the porous anodic alumina substrate via anodic oxidation, then self-assembling and growing the metal halide-oxide nanosheets, and finally using copper hexafluoroacetylacetone as a copper precursor and diethylzinc as a reducing agent, employing ALD to precisely control the particle size and distribution of the copper nanoparticles. This sensor is used for trace doxorubicin detection, with a detection limit as low as 0.5 ppm, covering the clinical therapeutic drug monitoring concentration range. It has the advantages of low cost, high sensitivity, and controllable structure. This invention provides a low-cost, high-sensitivity, structurally controllable, and highly consistent SERS sensor for trace doxorubicin detection.

This invention discloses a targeted nanodelivery system, its preparation method, and its applications. The targeted nanodelivery system is a pH / ROS-responsive sustained-release system loaded with chlorophyll copper / doxorubicin / NO donors. Specifically, it includes: a carrier material: a polythioacetal formed by the dimethylchlorosilane-catalyzed dehydration condensation of 4-formylphenylboronic acid and 3,6-dioxa-1,8-octanedithiol; a system modification component: DSPE-PEG-methyl; and active ingredients: doxorubicin as a chemotherapeutic drug, sodium chlorophyll copper as a photosensitizer / adjuvant therapy component, and N,N′-disec-butyl-N,N′-dinitroso-1,4-phenylenediamine as a NO donor. This nanodelivery system based on a dual-response mechanism provides a new and effective strategy for the precise and synergistic treatment of gliomas and has the potential for further clinical translation.

This invention provides an Auger electron radiotherapy drug that can selectively and effectively release a sufficient amount of Auger electrons into the nuclear DNA of cancer cells, even in small amounts, thereby reducing or killing cancer cells. The Auger electron radioactive isotope has a half-life that is not too short but not too long, making it highly safe and readily available. [Solution] The Auger electron radioactive therapeutic agent is encapsulated in a stimulus-responsive liposome that accumulates in cancer tissue and / or cancer cells, such that an anthracycline derivative is released upon stimulation, in which an Auger electron-emitting radioisotope-substituted benzene ring-containing group or radioisotope-substituted alkyl group is covalently bonded to the keto or amino group of anthracyclines selected from doxorubicin or daunorubicin and their reduced forms or alkoxy group-substituted forms thereof, is a stimulus-responsive liposome, or is bound to an antibody, oligopeptide, or antigen that accumulates in cancer tissue and / or cancer cells via a stimulus-responsive linker.

This invention belongs to the field of traditional Chinese medicine, specifically relating to a traditional Chinese medicine composition for preventing and treating cardiotoxicity induced by doxorubicin and its application; the traditional Chinese medicine composition for preventing and treating cardiotoxicity induced by doxorubicin is composed of ginseng and salvia miltiorrhiza; this invention finds that the traditional Chinese medicine composition can promote the survival rate of doxorubicin-induced cardiomyocyte H9c2, reduce doxorubicin-induced apoptosis of cardiomyocyte H9c2, reduce doxorubicin-induced oxidative stress damage and cardiac damage, improve left ventricular function, and improve doxorubicin-induced cardiotoxicity, which is of great significance for the prevention and treatment of azithromycin-induced cardiotoxicity.

This invention proposes an antitumor drug, its preparation method, and its application, belonging to the field of pharmaceutical technology. Fe3O 4 Polydopamine is deposited on the surface of NPs, and then a COF layer is formed on the surface through a one-pot method, and an antitumor compound is loaded onto it. Doxorubicin is further loaded onto the surface, and then reacted with F127 coupled with folic acid and oligomeric hyaluronic acid to obtain the antitumor drug. The antitumor drug prepared by this invention has high anticancer activity and drug resistance reversal, high drug loading rate, is not prone to aggregation, has good biocompatibility, and good targeting and sustained-release properties. It has good applications in chemotherapy, photodynamic therapy, photothermal therapy, and MRI, making it a new generation of integrated diagnostic and therapeutic reagent.

This invention relates to a multi-metal synergistic network nanoplatform, characterized in that the multi-metal synergistic network nanoplatform comprises particles and a framework, the particles comprising copper-containing particles and iron, the framework comprising manganese dioxide, and the particles being doped into the framework. The preparation method of the multi-metal synergistic network nanoplatform includes the following steps: preparation of the framework; preparation of the iron-doped framework; and preparation of the nanoplatform. This invention also provides a drug for treating tumors, comprising a drug and the multi-metal synergistic network nanoplatform, the drug comprising doxorubicin. This invention constructs a highly efficient multi-metal electronic synergistic network nanoplatform, systematically achieving efficient synergy and cascade enhancement of multiple treatment modalities, forming a multi-mechanism synergistic therapeutic system of "photothermal-chemotherapy-chemokinetics-immunoactivation".

This invention discloses a biomimetic hybrid liposome nanomedicine co-loaded with senolytic drugs and antibiotics, its preparation method, and its applications. The nanomedicine uses egg yolk lecithin and cholesterol as lipid materials. The Bcl-2 / Bcl-xL inhibitor ABT-263 is loaded into a lipid bilayer, and the antibiotic ciprofloxacin hydrochloride is encapsulated in an aqueous core. After preparing co-loaded liposomes using a thin-film hydration-ultrasound-extrusion-ultrafiltration method, the liposomes are fused with doxorubicin-induced senescent tumor cell membranes via ultrasound-assisted physical extrusion. The resulting biomimetic hybrid liposome possesses multiple functions, including homologous targeting of senescent tumor cells, selective removal of senescent cells, and killing of senescent bacteria. Combined use with 5-fluorouracil can enhance the killing effect on senescent tumor cells. This invention belongs to the field of biomedical nanotechnology.

This invention discloses a ZIF-8 nanomedicine delivery system co-loaded with doxorubicin and siTDRKH, its preparation method, and its applications, belonging to the fields of biomedicine and nanomaterials technology. The nanomedicine delivery system uses the zeolite imidazole ester framework material ZIF-8 as a carrier. Its porous structure encapsulates the chemotherapeutic drug doxorubicin within the framework, and small interfering RNA targeting the TDRKH gene is loaded onto the surface through electrostatic adsorption. This structure exhibits high pH responsiveness: it remains stable under normal physiological conditions (pH 7.4), preventing premature drug leakage; upon entering the slightly acidic environment of a tumor (pH 6.5) or a lysosomal environment (pH 5.0), the ZIF-8 framework immediately disintegrates, achieving targeted and synergistic release of the loaded drug.